Диссертация (1141228), страница 19
Текст из файла (страница 19)
Ann Intern Med. 2009; 150 (5): 293- 300.45.Crowther M.A., Julian J., McCarty D. et al. Treatment of warfarin- asso-ciated coagulopathy with oral vitamin K: a randomized controlled trial. Lancet.2000; 356 (9421): 1551- 1553.46.Crowther M.A., Ginsberg J.B., Kearon C. et al. A randomized trial compar-ing 5 mg and 10 mg warfarin loading doses. Arch Intern Med 1999; 159:46–48.47.Cushman M., Tsai A.W., White R.H., Heckbert S.R., Rosamond W.D., En-right P., Folsom A.R.
Deep vein thrombosis and pulmonary embolism in twocohorts: the longitudinal investigation of thromboembolism etiology. Am J Med.2004; 117: 19 -25.11048.Dager W.E., King J.H., Regalia R.C. et al. Reversal of elevated internationalnormalized ratios and bleeding with low-dose recombinant activated Factor VII inpatients receiving warfarin. Pharmacology. 2006; 26:1091–1098.49.David Snipelisky, Fred Kusumoto. Current strategies to minimize thebleeding risk. J of Blood Medicine.
2013:4 89- 99.50.De Godoy J.M., de Godoy M.F., Braile D.M. Recurrent thrombosis in pa-tients with deep vein thrombosis and / or venous thromboembolism associated withanticardiolipin antibodies. Angiology. 2006; 57: 79 -83.51.Dentali F., Ageno W., Crowther M. Treatment of coumarin-associated co-agulopathy: a systematic review and proposed treatment algorithms. J ThrombHaemost. 2006;4:1853–63.52.Dentali F., Crowther M.A. Management of excessive anticoagulant effectdue to vitamin K antagonists. Hematology. 2008; 266–270.53.Dezee K.J., Shimeal W.T., Douglas K.M., Shumway N.M., O’ malley P.G.Treatment of excessive anticoagulation with phytonadion (vitamin K): a metaanalysis. Arch Intern Med.
2006; 166 (4): 391- 397.54.DiMarco J.P., Flaker G., Waldo A.L. et al. Factors affecting bleeding riskduring anticoagulant therapy in patients with atrial fibrillation: observa-tions fromthe Atrial Fibrillation Follow- up Investigation of Rhythm Man-agement(AFFIRM) Study. Am Heart J. 2005; 149 (4):650- 656.55.Douketis J.D., Kearon C.B., Bates S., Duku E.K., Ginsberg J.S. The risk offatal pulmonary embolism in patients with treated venous thromboem-bolism.JAMA. 1998;279458- 462.56.Douketis J.D., Foster G.A., Crowther M.A., Prins M.H., Ginsberg J.S.Clinical risk factors and timing of recurrent venous thromboembolism during theinitial 3 months of anticoagulant therapy.
Arch Intern Med 2000, 160:3431-3436.11157.Douketis J.D., Crowther M.A., Foster G.A., Ginsberg J.S. Does the loca-tionof thrombosis determine the risk of disease recurrence in patients with proximaldeep vein thrombosis? Am J Med. 2001; 110: 515 -519.58.Douketis J.D., Gu C.S., Schulman S., Ghirarduzzi A., Pengo V., Prandoni P.The risk for fatal pulmonary embolism after discontinuing anticoagulant ther-apyfor venous thromboembolism. Ann Intern Med. 2007; 147: 766–774.59.Douketis J.D. Perioperative management of patients who are receivingwarfarin therapy: an evidence-based and practical approach.
Blood 2011;117:5044.60.Durai R., Fogarty S. A penetrating inferior vena cava filter // European J.Vascular Endovascular Surgery. 2006. V. 32. № 6. P. 737–739.61.Eby C.S. Warfarin-induced skin necrosis. Hematol Oncol Clin North Am.1993;7:1291-300.62.Evans G., Luddington R., Baglin T. Beriplex P/N reverses severe warfarininduced overanticoagulation immediately and completely in patients presentingwith major bleeding.
Br J Haematol. 2001;115:998–1001.63.Gallego P., Apostolakis S., Lip G.Y. Bridging evidence-based practice andpractice-based evidence in periprocedural anticoagulation. Circulation 2012;126:1573.64.Garcia D.A., Lopes R.D., Hylek E.M. et al. New- onset atrial fibrillationand warfarin initiation: high risk periods and implications for new antithrom-boticdrugs.
Thromb Haemost. 2010; 104 (6): 1099- 1105.65.Garcia-Fuster M.J., Forner M.J., Fernandez C., Gil J., Vaya A., MaldonadoL. Long-term prospective study of recurrent venous thromboembolism in pa-tientsyounger than 50 years. Pathophysiol Haemost Thromb. 2005; 34: 6 -12.66.Giovanni B., Samantha P., Alfredo B., Vincenzo D. A. Emergency rever-salof anticoagulation: from theory to real use of prothrombin complex concen-trates.A prospective Italian experience. Blood Transfus. 2012; 10: 87- 94.11267.Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep veinthrombosis.
Lancet 2012;379:1835-1846.68.Goodnough L.T., Shander A. How I treat warfarin-associated coagulopa-thyin patients with intracerebral hemorrhage.. Blood 2011, 117:6091-6099.69.Gordon H. Guyatt, Elie A.; Mark Crowther, David D. Gutterman, Holger J.Schünemann. \\Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical PracticeGuidelines.- P. 95.70.Greenblatt D.J., von Moltke L.L. Interaction of warfarin with drugs, natu-ralsubstances, and foods.
J Clin Pharmacol 2005;45:127-32.71.Haemostasis and Thrombosis Task Force for the British Committee forStandards in Haematology Guidelines on oral anticoagulation. Third edition. Br JHaematol. 1998;101:374–87.72.Hanley P. Warfarin reversal.
J Clin Pathol. 2004;57:1132–9, Dickneite G.Prothrombin complex concentrate versus recombinant factor VIIa for rever-sal ofcoumarin anticoagulation. Thromb Res. 2007;119:643–51.73.Heit J.A. The epidemiology of venous thromboembolism in the commu-nity:implications for prevention and management. J Thromb Thrombolysis 2006;21:23-29.74.Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O'Fallon W.M.,Melton L.J. Predictors of recurrence after deep vein thrombosis and pulmonaryembolism: a population-based cohort study. Arch Intern Med. 2000; 160: 761 -768.75.Heit J.A., Silverstein M.D., Mohr D.N.
et al: Risk factors for deep veinthrombosis and pulmonary embolism: A population-based case-control study. ArchIntern Med 160:809-815, 2000.76.Hirsch J., Fuster V., Ansell J. et al. American Heart Association/AmericanCollege of Cardiology Foundation Guide to Warfarin Therapy. J Am Coll Car-diol.2003; 41:1633–1652.11377.Hirsh J., Fuster V., Ansell J., Halperin J.L. American Heart Associa-tion/American College of CardiologyFoundation. Guide to Warfarin Therapy.Circulation, 2003: 1692-1711.78.Holbrook A., Schulman S., Witt D.M.
et al. Evidence-based manage-ment ofanticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9thed: American College of Chest Physicians evidence-based clin-ical practiceguidelines. Chest. 2012;141(2)(suppl):e152S-e184S.79.Holbrook A.M., Pereira J.A., Labiris R. et al. Systematic overview ofwarfarin and its drug and food intractions.
Arch. Intern Med. 2005; 165 (10): 10951106.80.Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., Buller HR.Inci-dence of recurrent thromboembolic and bleeding complications amongpatients with venous thromboembolism in relation to both malignancy andachieved in-ternational normalized ratio: a retrospective analysis. J Clin Oncol.2000; 18: 3078 -3083.81.Hylek E.M., Chang Y.C., Skates S.J. et al. Prospective study of the out-comes of ambulatory patients with excessive warfarin anticoagulation.
Arch InternMed. 2000; 160 (11): 1612- 1617.82.Hylek E.M., Evance- Molina C., Shea C., Henault L.E., Regan S. Majorhemorrhage and tolerability of warfarin in the first year of therapy among el-derlypatients with atrial fibrillation. Circulation. 2007; 115 (21): 2689- 2696.83.Italian Federation of Anticoagulation Clinics A guide to oral anticoagu-lanttherapy.
Haemostasis. 1998;28(Suppl 2):1–46.84.Iung B., Rodes-Cabau J. The optimal management of anti-thrombotictherapy after valve replacement: certainties and uncertainties // Eur. Heart J. 2014. - Vol. 35. - P. 2942-2949.85.Jaffer A.K. Perioperative management of warfarin and antiplatelet thera-py.Cleve Clin J Med 2009; 76 Suppl 4:S37.11486.Jose M. S., Fernando T., Wander E. S., Igor S. P., Domingos M. F. Skin ne-crosis induced by vitamin K antagonists. J.
Vasc. Bras. vol.8 no.4 Porto AlegreDec. 2009.87.Kakkar V.V., Cohen A.T., Edmonson R.A. et al. Low molecular weight ver-sus standard heparin for prevention of venous thromboembolism after majorabdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341:259.88.Kaplan-Machlis B., Klostermeyer B.S. The cyclooxygenase-2 inhibitors:safety and effectiveness. Ann Pharmacother. 1999;33:979–88.89.Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., TurpieA.G., Green D., Ginsberg J.S., Wells P., MacKinnon B., Julian J.A. A comparisonof three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med.
1999; 340: 901 -907.90.Kearon C., Ginsberg J.S., Kovacs M.J. et al. Extended Low- IntensityAnticoagulation for Thrombo- Embolism Investigators. Comparison of lowintensity warfarin therapy with conventional- intensity warfarin therapy for longterm prevention of reccurent venous thromboembolism. N Engl Med. 2003; 349(7): 631- 639.91.Kelton J.G., Smith J.W., Warkentin T.E., Hayward CPM, Denomme G.A.,Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood.1994;83:3232–3239.92.Khan H., Belsher J., Yilmaz M. et al.
Fresh-frozen plasma and platelettransfusions are associated with development of acute lung injury in critically illmedical patients. Chest. 2007;;131:1308–1314.93.Kim T.M., Kim J.S., Han S.W., Hong Y.S., Kim I., Ha J., Kim S.J., ChungJ.W., Park J.H., Lee D., Park S., Kim B.K., Kim N.K., Yoon S.S. Clinical115predictors of recurrent venous thromboembolism: A single institute experience inKorea. Thromb Res.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
